The Modified "Pills-in-the-Pocket" Strategy -The Combined Effect of Amiodarone, Bisoprolol and Digoxin in the Treatment of Recurrent Atrial Arrhythmia for Non-Paroxysmal Atrial Fibrillation After Catheter Ablation: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Clinical Trial

This is a multicentre, prospective, randomised controlled study of 328 patients with non-paroxysmal AF (within 5 years of first diagnosis of AF) with recurrent atrial arrhythmias after first catheter ablation, randomly divided in a 1:1 ratio into a study group treated with triple AADs (amiodarone + bisoprolol + digoxin) and a control group treated with conventional AADs (amiodarone + bisoprolol + digoxin). The study group was treated with triple AADs (amiodarone + bisoprolol) and the control group was treated with conventional AADs (amiodarone + bisoprolol) with the aim of comparing the efficacy and safety of the two groups in terms of reversion of SR, which may provide an effective option of pocket drug reversion for patients with recurrence of SR after AF catheter ablation.
Translated with DeepL.com (free version)

开始日期2024-10-23

申办/合作机构

广东省人民医院

[+6]

ChiCTR2400090581 / SuspendedN/AIIT

Exploring Inflammatory, Immune, and Metabolic Targets and Mechanisms Related to Postoperative Delirium through Multi-omics Approaches

开始日期2024-10-15

申办/合作机构

广东省人民医院

ChiCTR2400089689 / Suspended临床3期IIT

A Clinical Trial to Evaluate the Efficacy and Safety of HX-1 Cardioplegic Solution in Inducing Cardiac Arrest and Myocardial Protection During Cardiopulmonary Bypass Surgery

开始日期2024-09-25

申办/合作机构

广东省人民医院

100 项与广东省人民医院相关的临床结果

登录后查看更多信息

0 项与广东省人民医院相关的专利（医药）

登录后查看更多信息

3,995

项与广东省人民医院相关的文献（医药）

2024-09-01·JTO Clinical and Research Reports

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

Article

作者: Yang, Jin-Ji ; Cheng, Ying ; Xu, Tingting ; Kim, Sang-We ; Qian, Li ; Lu, You ; Zhang, Li ; Reungwetwattana, Thanyanan ; Liu, Zhe ; Lee, Se-Hoon ; Zhou, Mingzhu ; Zhou, Caicun ; Hilton, Magalie ; Zhang, Yiping ; Archer, Venice ; Fang, Jian ; Zhou, Jianying ; Chang, Jianhua ; Bu, Lilian ; He, Jianxing

IntroductionPrevious results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the "last patient in" date.MethodsAdult patients with treatment-naïve, advanced ALK-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, time to CNS progression, and safety.ResultsAt the data cutoff (May 16, 2022), the median survival follow-up was 61 and 51 months in the alectinib and crizotinib arms, respectively. Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib (stratified hazard ratio = 0.33, 95% confidence interval: 0.23-0.49). Overall survival data remain immature; 5-year overall survival rates were 66.4% (alectinib arm) versus 56.1% (crizotinib arm). Objective response rate was 91.2% versus 77.4% with alectinib and crizotinib, respectively. CNS progression was delayed with alectinib versus crizotinib (cause-specific hazard ratio = 0.16, 95% confidence interval: 0.08-0.32). Median treatment duration was longer with alectinib versus crizotinib (42.3 versus 12.6 mo). No new safety signals were observed.ConclusionsWith four additional years of follow-up, these updated results confirm the clinical benefit and manageable safety of alectinib in Asian patients with advanced ALK-positive NSCLC, and confirm alectinib as a standard-of-care treatment for patients with advanced ALK-positive NSCLC.

2024-07-01·Journal of Medical Genetics

ZFHX3 variants cause childhood partial epilepsy and infantile spasms with favourable outcomes

Article

作者: Li, Bing-Mei ; Wang, Peng-Yu ; Yi, Yong-Hong ; Liu, Xiao-Rong ; He, Ming-Feng ; Zhai, Qiong-Xiang ; Zou, Dong-Fang ; He, Na ; Ma, Hai-Yan ; Guo, Jia-Jun ; He, Su-Li ; Qiao, Jing-Da ; Liao, Wei-Ping ; Wang, Juan ; Liu, Li-Hong ; Luo, Sheng ; Zhou, Peng

Background The ZFHX3 gene plays vital roles in embryonic development, cell proliferation, neuronal differentiation and neuronal death. This study aims to explore the relationship between ZFHX3 variants and epilepsy. Methods Whole-exome sequencing was performed in a cohort of 378 patients with partial (focal) epilepsy. A Drosophila Zfh2 knockdown model was used to validate the association between ZFHX3 and epilepsy. Results Compound heterozygous ZFHX3 variants were identified in eight unrelated cases. The burden of ZFHX3 variants was significantly higher in the case cohort, shown by multiple/specific statistical analyses. In Zfh2 knockdown flies, the incidence and duration of seizure-like behaviour were significantly greater than those in the controls. The Zfh2 knockdown flies exhibited more firing in excitatory neurons. All patients presented partial seizures. The five patients with variants in the C-terminus/N-terminus presented mild partial epilepsy. The other three patients included one who experienced frequent non-convulsive status epilepticus and two who had early spasms. These three patients had also neurodevelopmental abnormalities and were diagnosed as developmental epileptic encephalopathy (DEE), but achieved seizure-free after antiepileptic-drug treatment without adrenocorticotropic-hormone/steroids. The analyses of temporal expression (genetic dependent stages) indicated that ZFHX3 orthologous were highly expressed in the embryonic stage and decreased dramatically after birth. ConclusionZFHX3 is a novel causative gene of childhood partial epilepsy and DEE. The patients of infantile spasms achieved seizure-free after treatment without adrenocorticotropic-hormone/steroids implies a significance of genetic diagnosis in precise treatment. The genetic dependent stage provided an insight into the underlying mechanism of the evolutional course of illness.

2024-05-20·Chinese Medical Journal

Clinical application and management of temporary mechanical circulatory support: A clinical consensus

Article

作者: Chen, Xin ; Zhang, Haitao ; Hou, Xiaotong ; Vincentelli, André ; Chen, Liangwan ; Xiao, Yingbin ; Wang, Xianqiang ; Dong, Nianguo ; Yanase, Masanobu ; Sodha, Neel ; Maureira, Juan Pablo ; Wang, Huishan ; Atluri, Pavan ; Folliguet, Thierry ; Wang, Yixuan ; Leprince, Pascal ; Huang, Jinsong ; Takami, Yoshijuki ; Yan, Yang ; Sellke, Frank W ; Bonde, Pramod

176

项与广东省人民医院相关的新闻（医药）

2024-10-30

·药渡Daily

浦合医药第4代EGFR抑制剂完成首例受试者入组

近日，苏州浦合医药自主研发的潜在Best-in-class第4代EGFR口服小分子抑制剂PH009-1在广东省人民医院完成首例受试者入组。 PH009-1的I/IIa期临床试验是由广东省人民医院吴一龙教授牵头的一项全国多中心研究。I期试验包括剂量递增和剂量扩展两部分，旨在评价PH009-1在NSCLC耐药受试者中的安全性、耐受性、药代动力学特性和初步的抗肿瘤活性，确定最大耐受剂量（MTD）或II 期临床试验推荐剂量（RP2D）。 PH009-1是浦合医药自主研发的拥有完全自主知识产权的新分子实体，在临床前数据中展现出广谱性和高选择性的双重优势。PH009-1可全面抑制EGFR经典突变 (19del或L858R）以及常见耐药突变（包括: 19del或L858R合并 T790M, C797S双突变或三突变)。同时PH009-1对野生型EGFR和其他激酶抑制较弱，具有良好的选择性及极低的脱靶风险。 PH009-1显著的抗肿瘤活性和良好的安全性使其在EGFR突变NSCLC领域展现出广泛的临床应用潜力。尤其是对于第一代（如吉非替尼）、第二代（如阿法替尼）及第三代 (如奥希替尼等) EGFR抑制剂耐药的非小细胞肺癌(NSCLC)患者，可提供更加有效，安全，便捷的治疗选择，以解决当前EGFR抑制剂耐药患者紧迫的临床需求。关于浦合医药苏州浦合医药科技有限公司成立于2021年4月，由国内上市医疗企业与私募股权医药产业基金拾玉投资共同出资孵化，专注于精准治疗的小分子创新药研究与开发，力争成为立足国内、面向全球的领先型Bio-pharma公司。公司秉持满足临床差异化需求的策略，聚焦肺癌、胰腺癌、消化道肿瘤等国内外高发病率和高死亡率的癌种，以科学和产业思维全方位布局，通过引进和自研等多重手段积极拓展创新药项目开发机会，整合资源快速推动公司产业化发展。公司从分子靶点出发，融合新一代激酶、别构抑制剂、合成致死、Protac等多种技术手段解决问题，已建成独特的小分子创新药开发平台，具备从靶点发现、分子结构设计、生物体内外活性、安全性及药代动力学评估、注册申报、临床I、II、III期试验开展和产品生产等各个环节的开发能力。与此同时公司的临床前项目储备丰富，未来计划每年有2-4个产品推向临床，多个产品采取国际多中心的临床模式。

蛋白降解靶向嵌合体临床1期

2024-10-25

·ioncology

ESMO ASIA 2024丨一文了解胸部肿瘤口头报告

点击蓝字关注我们 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia Congress 2024）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，近日在官方网站正式公布本次大会的摘要题目及作者信息。肿瘤瞭望小编带您先睹为快，一览胸部肿瘤领域入选优选口头报告（Proffered Paper）和微型口头报告（Mini Oral）的临床研究。 1 优选口头报告（Proffered Paper）摘要号：LBA8 英文标题：Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study 中文标题：阿替利珠单抗+卡铂/紫杉醇治疗转移性或复发性胸腺癌的II期临床试验：Marble研究讲者：Tomoyasu Mimori (日本) 摘要号：625O 英文标题：Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial 中文标题：Lucitanib在晚期复发或转移性胸腺癌二线或后续治疗中的疗效和安全性：一项随机、双盲、安慰剂对照的多中心II期试验讲者：方文涛（上海交通大学医学院附属胸科医院）摘要号：LBA5 英文标题：Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of Beamion LUNG-1 中文标题：Zongertinib治疗HER2突变型NSCLC患者：Beamion LUNG-1的最新分析讲者：Noboru Yamamoto (日本) 摘要号：LBA6 英文标题：PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT) 中文标题：PACIFIC-5：针对同步或序贯放化疗（cCRT或sCRT）后未出现进展不可切除III期NSCLC患者进行巩固性度伐利尤单抗治疗的III期研究讲者：吴一龙（广东省人民医院）摘要号：LBA7 英文标题：Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled analysis of TROPION-Lung01 and TROPION-Lung05 中文标题：Dato-DXd对既往接受过治疗的EGFR突变晚期非小细胞肺癌患者的疗效和安全性：TROPION-Lung01和TROPION-Lung05的汇总分析讲者：Myung-Ju Ahn (韩国) 2 微型口头报告（Mini Oral）摘要号：626MO 英文标题：Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase 2 DeLLphi-301 study 中文标题：Tarlatamab治疗既往接受过治疗的小细胞肺癌：II期DeLLphi-301研究中亚洲地区患者的亚组分析讲者：Hiroaki Akamatsu (日本) 摘要号：627MO 英文标题：POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small Cell Lung Cancer (mNSCLC) 中文标题：POD1UM-304：Retifanlimab+铂类化疗作为非鳞或鳞状转移性非小细胞肺癌一线疗法的III期研究讲者：陆舜(上海交通大学医学院附属胸科医院) 摘要号：614MO 英文标题：A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER Study) 中文标题：Becotatug联合奥希替尼治疗经典型EGFR突变非小细胞肺癌患者的Ⅱ期BOOSTER临床研究讲者：张力(中山大学肿瘤防治中心) 摘要号：630MO 英文标题：First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort 中文标题：一线奥希替尼±铂类-培美曲塞化疗治疗EGFR突变晚期非小细胞肺癌：FLAURA2亚洲队列讲者：James Chih-Hsin Yang (中国台湾) 摘要号：628MO 英文标题：Comparing Subcutaneous vs Intravenous Amivantamab with Lazertinib in EGFR-Mutated Advanced NSCLC: Analysis of Asian Patients From PALOMA-3 中文标题：比较皮下注射vs静脉注射Amivantamab联合Lazertinib治疗EGFR突变晚期NSCLC：对PALOMA-3亚洲患者的分析讲者：Se-Hoon Lee (韩国) 摘要号：629MO 英文标题：ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC) 中文标题：ALESIA研究7年随访更新：阿来替尼vs克唑替尼在未经治疗的晚期ALK+非小细胞肺癌亚洲患者中的疗效对比讲者：周彩存(上海市东方医院) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期临床结果临床3期

2024-10-18

·PRNewswire

Ping An Health Upgrades Chronic Disease Management Services with Significant Results in Digital Weight Management Program

HONG KONG and SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- The Weight Management and Public Health Action Conference, hosted by the National Center for Chronic and Noncommunicable Disease Control and Prevention ("NCNCD") and its affiliated institution, the Binhai Institute for Chronic Disease Control and Prevention and Health Innovation, and co-organized by Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK), recently concluded successfully. At the conference, Ping An Health announced a comprehensive upgrade to its chronic disease management services, expanding from "Three Controls and One Reduction" (blood sugar control, blood pressure control, and weight management) to "Five Controls and One Reduction." The upgraded program incorporates prevention and management solutions for fatty liver disease, hyperuricemia, and hyperlipidemia. It also includes comprehensive plans for integrating and connecting intelligent wearable devices and offline medical services. This upgrade significantly expands the scope of chronic disease control and prevention, providing customers with more comprehensive health management services. Additionally, Ping An Health has signed agreements with major tertiary hospitals, including Guangdong Second Provincial General Hospital, to jointly promote online and offline collaborative projects for chronic disease reversal, such as the reversal of diabetes and obesity. These initiatives create new avenues for customers to achieve worry-free, time-saving, and money-saving healthcare. Furthermore, NCNCD released the Digital Weight Management Research Report based on Ping An Health's chronic disease management program. The report highlights Ping An Health's digital weight management program, leveraging Ping An Jin Guan Jia and enterprise WeChat groups as primary management tools, effectively implemented a short-term, intensive training camp model for online adult weight management. Participants in the training camp achieved an average weight reduction of 1.5kg and a decrease in body mass index (BMI) of 0.6kg/m2, demonstrating a positive impact on improving their physical fitness. The program effectively reduced the proportion of overweight and obese individuals among participants within a specific timeframe, signifying its positive public health implications. NCNCD also joined forces with Ping An Health to launch the Intelligent Health Management Public Welfare Project for Professionals. This initiative aims to leverage Ping An Health's digital technology and intelligent tools to provide comprehensive health management services for employees across various enterprises nationwide, assisting them in effectively managing their weight and preventing chronic diseases. – End – About Ping An Healthcare And Technology Company Limited Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company"; Stock Code: 1833.HK), established in 2014, is the flagship of Ping An's healthcare and elderly care ecosystem. The Company was listed on the Main Board of HKEX on 4 May 2018. Ping An Health has leveraged its core competencies to enhance its managed care strategy. These competencies include rich payer resources for healthcare services such as insurance and financial clients, as well as corporate clients. Ping An Health is also empowered by its extensive supplier network, comprehensive service standard system, and strong Ping An ecosystem. Moreover, the Company is committed to building two main strategic pillars: "family doctor" and "senior care concierges". They focus on professional, comprehensive, high-quality, one-stop healthcare and senior care management services. Going forward, Ping An Health will adhere to the value proposition of "worry-free, time-saving and money-saving", with the vision "to provide every enterprise with a harmonious workplace, every family with a dedicated doctor, and every user with a safe and healthcare life". The Company will improve products with "ingenuity" and establish reputation with quality. Ping An Health will provide sustainable long-term value to users, shareholders and society through bridging doctors and patients with professionalism and safeguard everyone's health. SOURCE Ping An Healthcare and Technology Company Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED